Evidence map›Paper›PMID 42482806›Full record

ReviewRSC advances2026

AI-driven computational drug design: tools, workflow and challenges.

Ryena Dhir, Pitam Ghosh, Dinki Sharma, Vivek Asati

Abstract readReview
In one paragraph

Review in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ryena DhirDepartment of Pharmaceutical Chemistry, ISF College of Pharmacy Moga Punjab India vivekasatipharma47@gmail.com.
Pitam GhoshDepartment of Pharmaceutical Chemistry, ISF College of Pharmacy Moga Punjab India vivekasatipharma47@gmail.com.
Dinki SharmaDepartment of Pharmaceutical Chemistry, ISF College of Pharmacy Moga Punjab India vivekasatipharma47@gmail.com.
Vivek AsatiDepartment of Pharmaceutical Chemistry, ISF College of Pharmacy Moga Punjab India vivekasatipharma47@gmail.com.ORCID https://orcid.org/0000-0003-4990-7757

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug discovery is a time-consuming and resource-intensive process with a development period of more than ten years and a clinical attrition rate of more than 90%. Despite its contributions to rational drug design, computer-aided drug design has been constrained by limited scalability, overreliance on molecular descriptors, and incomplete modeling of complex biological systems. The emergence of artificial intelligence (AI) has transformed this landscape. AI-based drug discovery platforms have shifted the paradigm from a narrow focus to a comprehensive platform that covers target identification using graph-based drug-target interaction models. Additionally, deep-learning-based docking techniques, such as GNINA and AtomNet,

Identifiers

PMID42482806
PMCPMC13386871

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.